Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 16/20 | 0.64 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | CCNK | O75909 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10242094 | 1.00 | CDK9 (0.64) | CDK9CCNT1ABL1CCNK | |
| SCHEMBL10241764 | 0.94 | CDK9 (0.65) | CDK9CCNT1ABL1 | |
| SCHEMBL10241825 | 0.94 | CDK9 (0.65) | CDK9CCNT1ABL1 | |
| SCHEMBL1439854 | 0.92 | CDK9 (0.76) | CDK9CCNT1 | |
| SCHEMBL1439752 | 0.92 | CDK9 (0.76) | CDK9CCNT1 | |
| SCHEMBL1947160 | 0.89 | CDK9 (0.65) | CDK9CCNT1CCNK | |
| SCHEMBL1946889 | 0.89 | CDK9 (0.65) | CDK9CCNT1CCNK | |
| SCHEMBL1947627 | 0.89 | CDK9 (0.65) | CDK9CCNT1CCNK | |
| SCHEMBL1439108 | 0.88 | CDK9 (0.79) | CDK9CCNT1CCNK | |
| SCHEMBL1945690 | 0.88 | CDK9 (0.78) | CDK9CCNT1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | CDK9 6/4885CCNT1 80/4885ABL1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.